SHANGHAI


,


July 10, 2022


/PRNewswire/ — Qiming Venture Partners announced today the closing of its latest funds totaling

US$3.2 billion

, including USD Fund VIII at

US$2.5 billion

and the first closing of RMB Fund VII at

RMB 4.7 billion

(or

US$ 700 million

).

As in prior funds, Fund VIII was oversubscribed and reached its hard cap for limited partner commitments. This increases the firm’s capital raised to

$9.4 billion

across 18 funds.

Committed capital includes the Qiming Venture Partners Fund VIII main fund that focuses on early and growth stage Technology and Consumer (T&C) and Healthcare investments and the Qiming Venture Partners Fund VIII-HC parallel healthcare fund that invests alongside the main fund (collectively “Fund VIII”).

Fund VIII is led by Managing Partners Duane Kuang,

Nisa Leung

,

William Hu

, and

Gary Rieschel

, with full support of investment and administration teams based in

Shanghai

,

Beijing

,

Shenzhen

, and

Hong Kong

.

Since its inception in 2006, Qiming has demonstrated its ability to deliver consistently strong venture capital returns in

China

. Qiming has backed over 480 fast-growing companies, over 70 of which have achieved unicorn status. A vast majority of these companies were early stage at the time of initial investment. In addition, over 180 of our portfolio companies have achieved exits through IPO, M&A or other means, including Xiaomi, Gan & Lee Pharmaceuticals, Tigermed,

Zai Lab

, CanSino Biologics, APT Medical, Meituan, Bilibili and Roborock.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading

China

venture capital firm with offices in

Shanghai

,

Beijing

, Suzhou,

Hong Kong

,

Seattle

,

Boston

and the

San Francisco Bay Area

.

Currently, Qiming Venture Partners manages

eleven US Dollar

funds and

seven RMB

funds with

$9.4 billion

in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE: ZH, SEHK: 2390), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347),

Zai Lab

(NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Venus MedTech (SEHK:2500), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), Yuanxin Technology, dMed-Clinipace, Belief BioMed, WeRide, Biren Technology and UBTech among many others.

View original content:

https://www.prnewswire.com/news-releases/qiming-venture-partners-announces-closing-of-funds-totaling-us3-2-billion-301583471.html

SOURCE Qiming Venture Partners